Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, ethinylestradiol/drospirenone (Flexyess®) cannot be endorsed for use within NHS Wales as oral contraception. |
||
|
||
Medicine details |
||
| Medicine name | ethinylestradiol/drospirenone (Flexyess®) | |
| Formulation | 0.02 mg/3 mg film-coated tablet | |
| Reference number | 2021 | |
| Indication | Oral contraception |
|
| Company | Bayer Healthcare Pharmaceuticals | |
| BNF chapter | Obstetrics, gynaecology & urinary tract disorders | |
| Submission type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 29/07/2013 | |